556 related articles for article (PubMed ID: 31517034)
1. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
[TBL] [Abstract][Full Text] [Related]
2. Impact of β-blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation.
Galves R; Da Costa A; Pierrard R; Bayard G; Guichard JB; Isaaz K
Echocardiography; 2020 Sep; 37(9):1392-1398. PubMed ID: 32815195
[TBL] [Abstract][Full Text] [Related]
3. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
[TBL] [Abstract][Full Text] [Related]
4. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
[TBL] [Abstract][Full Text] [Related]
5. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
Shah AM; Claggett B; Prasad N; Li G; Volquez M; Jering K; Cikes M; Kovacs A; Mullens W; Nicolau JC; Køber L; van der Meer P; Jhund PS; Ibram G; Lefkowitz M; Zhou Y; Solomon SD; Pfeffer MA
Circulation; 2022 Oct; 146(14):1067-1081. PubMed ID: 36082663
[TBL] [Abstract][Full Text] [Related]
6. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
[TBL] [Abstract][Full Text] [Related]
7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
[TBL] [Abstract][Full Text] [Related]
9. Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
Bouali Y; Galli E; Paven E; Laurin C; Arnaud H; Oger E; Donal E
Adv Clin Exp Med; 2022 Feb; 31(2):109-119. PubMed ID: 34918885
[TBL] [Abstract][Full Text] [Related]
10. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
[TBL] [Abstract][Full Text] [Related]
11. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan.
Mantegazza V; Volpato V; Mapelli M; Sassi V; Salvioni E; Mattavelli I; Tamborini G; Agostoni P; Pepi M
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679543
[TBL] [Abstract][Full Text] [Related]
13. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
14. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
Naser N; Kulić M; Jatić Z
Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
De Vecchis R; Paccone A; Di Maio M
Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
[TBL] [Abstract][Full Text] [Related]
18. Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
Correale M; Mazzeo P; Magnesa M; Fortunato M; Tricarico L; Leopizzi A; Mallardi A; Mennella R; Tucci S; Brunetti ND
Clin Physiol Funct Imaging; 2021 Nov; 41(6):505-513. PubMed ID: 34510702
[TBL] [Abstract][Full Text] [Related]
19. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
Moon MG; Hwang IC; Choi W; Cho GY; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ
ESC Heart Fail; 2021 Jun; 8(3):2058-2069. PubMed ID: 33682334
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
